Reassuringly, in the study reported herein, no recipients of the CpG 10104 formulation of the vaccine developed antibodies to dsDNA, ANA, or rheumatoid factor, and none reported any symptoms concerning for autoimmune disease. This evidence concerns the gene BTG3 and autoimmune disease.